IBXXF (Imagion Biosystems) EBITDA: $-2.28 Mil (TTM As of Dec. 2025)


What is Imagion Biosystems EBITDA?

Imagion Biosystems IBXXF EBITDA is $-2.28 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

Imagion Biosystems's EBITDA for the six months ended in Dec. 2025 was $-1.65 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.28 Mil.

During the past 3 years, the average EBITDA Growth Rate was 26.50% per year. During the past 5 years, the average EBITDA Growth Rate was 21.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 9 years, the highest 3-Year average EBITDA Growth Rate of Imagion Biosystems was 53.20% per year. The lowest was -38.40% per year. And the median was 10.35% per year.

Imagion Biosystems's EBITDA per Share for the six months ended in Dec. 2025 was $-0.01. Its EBITDA per share for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.01.

During the past 3 years, the average EBITDA per Share Growth Rate was 66.20% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 49.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 9 years, the highest 3-Year average EBITDA per Share Growth Rate of Imagion Biosystems was 66.20% per year. The lowest was -12.10% per year. And the median was 44.70% per year.

Imagion Biosystems  (OTCPK:IBXXF) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Imagion Biosystems EBITDA Related Terms


Imagion Biosystems EBITDA Historical Data

* Premium members only.

The historical data trend for Imagion Biosystems's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imagion Biosystems EBITDA Chart

Imagion Biosystems Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA
Get a 7-Day Free Trial Premium Member Only -4.02 -5.87 -7.71 -0.36 -2.30

Imagion Biosystems Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.22 -0.36 -0.02 -0.64 -1.65

IBXXF vs TMO, DHR, IDXX: EBITDA Comparison

For the Diagnostics & Research subindustry, Imagion Biosystems's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imagion Biosystems EV-to-EBITDA vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Imagion Biosystems's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Imagion Biosystems's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Imagion Biosystems's EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Imagion Biosystems's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2025, Imagion Biosystems's EBITDA was $-2.30 Mil.

Imagion Biosystems's EBITDA for the quarter that ended in Dec. 2025 is calculated as

Imagion Biosystems's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Dec. 2025, Imagion Biosystems's EBITDA was $-1.65 Mil.

EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-2.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Frequently Asked Questions Learn more about EBITDA →
What does a EBITDA of $-2.28 Mil mean?
Imagion Biosystems (IBXXF) has a EBITDA of $-2.28 Mil as of Dec. 2025. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Imagion Biosystems.
Is Imagion Biosystems' EBITDA too high?
Imagion Biosystems' current EBITDA is $-2.28 Mil.
How does Imagion Biosystems' EBITDA compare to TMO and DHR?
Imagion Biosystems' EBITDA of $-2.28 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for a Medical Diagnostics & Research company?
A good EBITDA depends on the Medical Diagnostics & Research industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Imagion Biosystems. Imagion Biosystems's current EBITDA is $-2.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imagion Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Imagion Biosystems (IBXXF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.11, compared to a current price of $0.03 — trading 72.7% below its estimated fair value. The current EBITDA is $-2.28 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For Imagion Biosystems (IBXXF), the current EBITDA is $-2.28 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Imagion Biosystems Business Description

Other Exchanges IBX:Australia
Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3000
Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer. The company operates in Australia and the USA, with revenue from Australia.